Sotyktu

News

BMS’ Sotyktu cleared for NHS use in psoriasis

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.

News

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.

News

BMS scores first approval for psoriasis therapy Sotyktu

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatme

BMS’ Sotyktu cleared for NHS use in psoriasis

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

BMS scores first approval for psoriasis therapy Sotyktu

Agios shares slide as it abandons sickle cell candidate

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks